Table 2.
Meta-analyses on effects of comorbidities on COVID-19
| Condition | Included | Results of meta-analysis | References |
|---|---|---|---|
| Cancer | 10 studies | RR for death = 1.47 (95% CI: 1.01–2.14) | [39] |
| Cardiovascular disease | 13 studies 3027 patients | OR for critical/mortal patients = 5.19, 95% CI (3.25, 8.29) | [40] |
| 16 studies with 4448 patients | RR for death = 2.25 (95% CI: 1.53, 3.29) | [41] | |
| 14 studies | RR for death = 2.25 95% CI (1.60–3.17) | [39] | |
| Seven studies with 1576 patients | OR for severe disease = 3.42 (95% CI: 1.88–6.22) | [42] | |
| Cerebrovascular disease | Six studies with 1527 patients | RR for severe disease = 3.30, 95% CI (2.03, 5.36) | [43] |
| 16 studies with 4448 patients | RR for death = 2.38 (95% CI: 1.92, 2.96) | [41] | |
| Chronic kidney disease | Nine studies | RR for death = 3.25 (95% CI: 1.13–9.28) | [39] |
| Congestive heart failure | Three studies | RR for death = 2.03 (95% CI: 1.28–3.21) | [39] |
| COPD | 15 studies with 2473 patients | RR for sever disease = 1.88 (95% CI 1.4–2.4) | [44] |
| Eight studies | RR for death = 1.33 (95% CI: 0.77–2.31) | [39] | |
| Diabetes | Seven studies with 1576 patients | OR for severe disease = 2·07 (95% CI 0·88–4·82)a | [42] |
| 13 studies 3027 patients | OR for critical/mortal patients = 3.68 95% CI (2.68, 5.03) | [40] | |
| 30 studies with 6452 patients | RR for death = 2.12 95% CI (1.44, 3.11) | [45] | |
| 13 studies with 926 patients | OR for death = 1.75 95% CI (1.31–2.36) | [46] | |
| Four studies with 471 patients | OR for death = 3.21 95% CI (1.82–5.64) | [47] | |
| Six studies with 1687 patients | RR for severe disease = 2.26 (95% CI: 1.47–3.49) | [48] | |
| 65 studies with 15,794 patients | RR for death = 2.78 (95% CI: 1.39–5.58) | [49] | |
| Six studies with 1527 patients | RR for severe disease = 2.21, 95% CI (0.88, 5.57)a | [43] | |
| 33 studies with 16,003 patients | OR for death = 1.90 (95% CI: 1.37–2.64) | [50] | |
| 16 studies | RR for death = 1.48 (95% CI: 1.02–2.15) | [39] | |
| Hypertension | 19 studies with 15,302 cases | Adjusted OR for death = 1.44, 95% CI (1.24–1.66); I2 = 41.4% | [51] |
| Seven studies with 1576 patients | OR for severe disease = 2.36 (95% CI: 1.46–3.83) | [42] | |
| 13 studies 3027 patients | OR for critical/mortal patients = 2.72, 95% CI (1.60,4.64) | [40] | |
| 12 studies with 2389 patients | OR for death = 3.48 (95% CI: 1.72–7.08) | [52] | |
| Three studies with 419 patients | OR for death = 3.36 (95% CI: 1.96–5.7) | [53] | |
| 65 studies with 15,794 patients | RR for death = 2.39 (95% CI 1.54–3.73) | [49] | |
| six studies with 1527 patients | RR for severe disease = 2.03 95% CI (1.54, 2.68) | [43] | |
| 30 studies with 6560 patients | RR for death = 2.21 (95% CI: 1.74, 2.81) | [54] | |
| 13 studies | RR for death = 1.82 (95% CI: 1.43–2.32) | [39] | |
| Obesity | Six studies with 26,507 patients | OR for death = 3.68 95% CI (1.54–8.83) | [55] |
| Respiratory system | Seven studies with 1576 patients | OR for severe disease = 2.46 (95% CI: 1.76–3.44) | [42] |
| 13 studies 3027 patients | OR for critical/mortal patients = 5.15, 95% CI (2.51, 10.57) | [40] |